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ǳ-Aminobutyrate aminotransferase (GABA-AT) is a pyridoxal phosphate dependent homodimeric 
enzyme of 50-kD subunits. It is a potential drug target against epilepsy. The three-dimensional structure 
of GABA-AT is not experimentally known, and we thus resorted to homology modelling to build a model 
based on x-ray crystal structure of pig liver GABA-AT to 3.0 Å resolution. Knowledge of the three-
dimensional structure of GABA-AT would greatly advance the development of novel lead compounds 
targeting this molecule. The protein’s conservity was verified by performing multiple alignments using 
ClustalW and MUSCLE programs. The model was further checked for its correctness by predicting the 
2D and 3D structures, which validates the structure. 
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ǳ-Aminobutyrate aminotransferase, (GABA-AT) (4-amino-
butyrate aminotransferase, GABA transferase, GABA 
aminotransferase, 4-aminobutyrate transaminase and 
gamma-amino-N-butyrate transaminase) is a pyridoxal 
phosphate dependent homodimeric enzyme distributed 
widely in nature (Cooper, 1985). The enzyme GABA-AT 
has been purified and characterized in several labora-
tories (Bloch-Tardy et al., 1974). It is a homodimer of 50-
kD subunits, with each subunit containing an active-site 
PLP covalently bound to Lys-329 via a Schiff base. 
GABA-AT belongs to a large family of homologous 
aminotransferases (Mehta et al., 1993) which operate by 
the same basic mechanism consisting of two coupled 
half-reactions in which the PLP-cofactor oscillates 
between its pyridoxal and pyridoxamine forms. Together 
with the structurally well characterized enzymes ornithine 
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(DGD), GABA-AT belongs to the subfamily II of the family 
of PLP-dependent enzymes (Mehta and Chriten, 2000). 
The mechanism for GABA-AT is well known (Cooper, 
1985). In GABA-AT, the specific reaction converts GABA 
to succinic semialdehyde (Cooper, 1985). It is a target for 
neuroactive drugs because its inhibition alters the 
balance between its substrate GABA and the product L-
glutamate, which are respectively the major inhibitory and 
excitatory neurotransmitters in the brain. Selective 
inactivation by vinyl-GABA, a mechanism-based inhibitor 
of the enzyme (Lippert et al., 1977), is already success-
fully applied in the treatment of epilepsy (Davies, 1995). 
In fact, about one-quarter of epileptic patients worldwide 
(about 12 million people) do not respond to any marketed 
anticonvulsant drug. Therefore, the need for new 
anticonvulsant drugs is great (Rogawski and Potter, 
1990). A reduction in the concentrations of GABA has 
been implicated not only in the symptoms associated with 
epilepsy (Bakay and Harris, 1981) but also with several 
other neurological diseases such as Huntington’s chorea 
(Butterworth et al., 1993), Parkinson’s disease (Nishino et 






tardive dyskinesia (Gunne et al., 1984). Administration of 
GABA peripherally is not effective, because GABA, under 
normal conditions, cannot cross the blood-brain barrier; 
however, several other approaches have been taken to 
increase the brain concentrations of GABA. 
In 1999, the x-ray crystal structure of pig liver GABA-AT 
was reported at 3.0-Å resolution (Storici et al., 2004), 
which elucidated the active-site geometry and allowed 
conclusions to be drawn with respect to its specificity. 
The crystal structure of pig liver GABA-AT, is 96% 
identical to the human brain enzyme (De Biase et al., 
1995). The availability of the GABA-AT structure will 
assist the rational design of new neuroactive compounds 
of value in the treatment of the several neurological and 
psychiatric disorders accompanied by altered GABA 
levels.  
Epilepsy is a neurological condition, which affects the 
nervous system. It is also known as a seizure disorder 
(Bell and Sander, 2001). In earlier drug designing, drugs 
were always used as trial-and-error process. The 
conventional way of synthesizing drugs has always been 
a tedious process, consuming several years, huge man 
power and extremely expensive in order to come up with 
a single effective novel drug. Estimates of time and cost 
of currently bringing a new drug to market vary, but 7 to 
12 years and $ 1.2 billion are often cited (Shankar et al., 
2006). However, now it can be done efficiently in-silico, 
thereby saving huge funds and man power. The pipeline 
of drug discovery from idea to market consists of seven 
basic steps: disease selection, target selection, lead 
compound identification, lead optimization, preclinical 
trials, clinical trial testing and pharmacogenomic optimi-
zation. Knowing the target, that is, the 3D structure of the 
protein is very important. The 3D structure of protein 
targets is most often derived from x-ray crystallography or 
nuclear magnetic resonance (NMR) techniques or even 
homology modeling. Homology modeling is to build a 
three dimensional (3D) model for a protein of unknown 
structure (the target) based on one or more related 
proteins of known structure (the templates) (Blundell et 
al., 1987; Greer, 1990; Johnson et al., 1994; Bajorath et 
al., 1994; Sali, 1995; Sanchez and Sali, 1997). Homology 
modeling was performed in our study as the x-ray 
crystallographic structure is not available for GABA-AT of 
human source. It is an essential requirement for 
identifying the structural characteristics of this protein as 
target to find a suitable antiepileptic drug, which is the 
main objective of our study. 
 
 
MATERIALS AND METHODS 
 
The sequence of GABA-AT protein (500 amino acids) of human 
was downloaded for structural modeling from UniProtKB/Swiss-Prot 
(EC 2.6.1.19). The physical and chemical properties of the 
sequence were calculated by the program ProtParam. The com-
puted parameters for a given protein includes the molecular weight, 
theoretical pI, amino acid composition, atomic composition, 
extinction coefficient, estimated half life, instability index, aliphatic  




index and grand average of hydropathicity (GRAVY). Multiple 
alignments of the related sequences were performed using the 
online available ClustalW program (http://www.ebi.ac.uk/Tools/ 
clustalw2/index.html) (Thompson et al., 1994) accessible through 
the European Bioinformatics Institute and MUSCLE, a computer 
program for creating multiple alignments of protein sequences. 
Elements of the algorithm include fast distance estimation using 
kmer counting, progressive alignment using a new profile function 
we call the log-expectation score, and refinement using tree-
dependent restricted partitioning (Edgar, 2004)..  
Different servers, that is, TMHMM (Krogh et al., 2001), SOSUI 
(Hirokawa et al., 1998) and TMpred are programs that make a 
prediction of membrane-spanning regions and their orientation. The 
algorithm was based on the statistical analysis of TMbase, a 
database of naturally occurring transmembrane proteins. The pre-
diction was made using a combination of several weight-matrices 
for scoring (Hofman and Stoffel, 1993) which were accessed to 
validate the TM region of GATA-AT protein. TMHMM, a new 
membrane protein topology prediction method, is based on a 
hidden Markov model. The prediction of protein secondary structure 
is an important step for the prediction of protein‘s tertiary structure. 
Secondary structure of GABA-AT was taken from the JPRED, a 
server powered by the Jnet algorithm. The algorithm provides a 
three-state (a-helix, b-strand and coil) prediction of secondary 
structure at an accuracy of 81.5% (Cole et al., 2008). PSIPRED, a 
server that is able to complete predictions in most cases in less 
than 2 min and processes about 100 predictions, requires a day 
and produces two dimensional graphical results (McGuffin et al., 
2000). SABLE, a server for improved prediction of secondary 
structures uses evolutionary profiles and predicts relative solvent 
accessibility of an amino acid residue as a fingerprint of the overall 
packing (Adamczak et al., 2005) and PredictProtein , provides 
PROSITE sequence motifs, low complexity regions (SEG), nuclear 
localization signals, regions lacking regular structure (NORS) and 
predictions of secondary structure, solvent accessibility, globular 
regions, transmembrane helices, coiled-coil regions, structural 
switch regions, disulfide-bonds, sub-cellular localization, and 
functional annotations (Puntervoll et al., 2003; Rost et al., 2004; 
Bairoch et al., 1997; Ceroni et al., 2004). Comparison of the results 
of respective programs was performed. 
No x-ray crystallographic or NMR structure of this protein of 
human source has been determined, therefore homology modeling 
was performed. The process of building a comparative model is 
conceptually straight forward. The methodology itself can be 
described in four steps; identifying a suitable template, making an 
optimal target-template alignment, building the model and validating 
the model. The comparative model of GABA-AT was built using a 
web-based homology-modeling server,  
SWISS-MODEL (Jain, 2004; Stoermer, 2006) and MODWEB, a 
comparative modeling server is integrated as a module in 
MODBASE (Pieper et al., 2009). Models are built using comparative 
modeling by satisfaction of spatial restraints as implemented in 
Modeller (Sali and Blundell, 1993). Homology Modeling is 
performed in the following steps: Firstly, it searches for suitable 
template for the submitted protein by using BLAST program. In the 
second step, it selects the suitable templates with sequence identity 
of above 25%. The accuracy of a model depends upon the 
sequence similarity it shares with the template. Models with >50% 
sequence identity to templates are normally of high quality, with ~1 
Å root mean square (RMS) error for main chain atoms (equal to 
medium-resolution NMR or low resolution x-ray structures). Models 
that have 30 to 50% sequence identity are normally of medium 
accuracy with an RMS of ~1.5 Å (Kasteleijn-Nolst et al., 2007; 
Enyedy et al., 2001). Thirdly, once the 3D model is created, the 
important step and last step is evaluating the 3D model of the 
protein. Structure validation was performed using ANOLEA 
(http://www.fundp.ac.be/pub/ANOLEA.html), VERIFY-3D (Holm and 
Sander, 1992) and GROMOS 96 of SWISS-PDB server. The model  
 




Table 1. Multiple alignment score of GABA-AT protein. 
 
Sequence Name and length of amino acids Alignment Score (%) 
1 Homo Sapiens (500) 
Sequences (1:2), Sequences (1:3), Sequences (1:4), 
Sequences (1:5), Sequences (1:6), Sequences (1:7), 
Sequences (1:8), Sequences (1:9)  
94, 91, 91, 51, 44, 41 
40, 40 
    
2 Bos Taurus (500) 
Sequences (2:3), Sequences (2:4), Sequences (2:5), 
Sequences (2:6), Sequences (2:7), Sequences (2:8), 
Sequences (2:9)  
91, 91, 51, 45, 40, 40, 40 
    
3 Mus musculus (500) 
Sequences (3:4), Sequences (3:5), Sequences (3:6)  
Sequences (3:7), Sequences (3:8), Sequences (3:9) 
97, 50, 44, 41, 40, 40 
    
4 Rattus norvegicus (500) Sequences (4:5), Sequences (4:6), Sequences (4:7) Sequences (4:8) Sequences (4:9)  50, 44, 40, 40, 40 
    
5 Drosophila (486) Sequences (5:6), Sequences (5:7), Sequences (5:8) Sequences (5:9)  48, 42, 46, 44 
    
6 Caenorhabditis (483) Sequences (6:7), Sequences (6:8) Sequences (6:9)  43, 43, 41 
7 Schizosaccharomyces (474) Sequences (7:8), Sequences (7:9)  47, 46 
8 Saccharomyces (471) Sequences (8:9)  73 




obtained by MODWEB was verified by different programs provided 
on the platform of Structural Analysis and Verification Server 
(SAVES) (http://nihserver.mbi.ucla.edu/SAVES). We selected 
PROCHECK (Laskowski et al., 1993) and VERIFY_3D among the 
available programs on SAVES to evaluate the quality of our model. 
The solvation profile of the protein structure was obtained using 
SolvX server. It is useful for assessing the quality of a homology 




RESULTS AND DISCUSSION 
 
General information of protein 
 
The sequence of GABA-AT was analyzed by the com-
puter program Protparam in order to find the physical and 
chemical properties. The number of amino acids was 
500, molecular weight was 56438.9 and theoretical pI 
was 8.17. The amino acid composition showed that, the 
number of leucine (L) was the highest, that is, 49 (9.8%), 
number of negatively charged residues (aspartic acid and 
glutamic acid) was 57, number of positively charged 
residues (Arginine, Lysine) was 60, instability index was 
42.12 which classifies the protein as unstable, aliphatic 
index was 83.52 and the grand average of hydropathicity 
was -0.265.  
Multiple sequence alignment of amino acid sequences 
of GABA-AT protein of different organisms (Homo 
sapiens, Bos taurus, Mus musculus, Rattus norvegicus, 
Drosophila melanogaster, Caenorhabditis elegans, 
Schizosaccharomyces pombe, Saccharomyces cerevisiae 
and Ashbya gossypii) showed that they are very close to 
each other ranging from 40 to 97 % as shown in Table 1. 
Figure 1 shows the result of the multiple sequence align-
ment of the mentioned organisms using CLUSTALW 
program. Multiple alignment of GABA-AT protein shows 
that M. musculus and R. norvegicus had 97% identity as 
shown in Figure 1. From the cladogram, GABA-AT 
protein of R. norvegicus was found to be far from that of 





Different servers were accessed for accurate prediction 
analysis of transmembrane region such as TMHMM, 
SOSUI and TMpred. The possible transmembrane 
helices of the sequence were from positions 202 to 225 
with score 225; 150 to 179 with score 132 and 210 to 226 
with score 555. Only scores above 500 were considered 
significant, that is, only one strong transmembrane was 
present with score 555.  
Table 2 summarizes the result of TMpred showing the 
significant possible transmembrane helices and Figure 3 
shows the transmembrane helices. The principal idea 
underlying most secondary structure prediction methods 
is the fact that segments of con-secutive residues have 
preferences for certain secondary structure states. 
Performance accuracy seemed to have been limited to 
about 60%. The limited accuracy was argued to result 
from the fact that all the methods used only information 
that were local in sequence.  
 










Secondary structure prediction 
 
There are several programs available to predict the 
secondary structure. We selected the following servers in 
order to   predict   the   secondary   structure:   PSIPRED, 
JPRED, PredictProtein and SABLE. Table 3 shows the 
result of the different servers; it shows the location of 
helices, sheets and coils. There was a minute difference 
in the positions of the helices, sheet and coils but it was 
negligible. The consensus regions of alpha  helices,  beta  
 

















Table 2. Significant possible transmembrance helices of GABA-AT; 
only scores above 500 are considered significant. 
 
S/N 
Strong transmembrane helix 
From To score 
1 202 225 225 
2 150 179 132 
3 210 226 555 
strands and coils for the three servers were chosen which 
are as follows: residues 3 to 12, 28 to 34, 100 to 104, 110 
to 124, 136 to 150, 166 to 181, 220 to 229, 306 to 320, 
326 to 342, 363 to 370, 383 to 400, 401 to 425, 444 to 
460 and 478 to 499 were involved in the alpha-helices 
formation, residues from 75 to 81, 83 to 88, 92 to 97, 156 
to 163, 209 to 216, 289 to 295, 319 to 336, 349 to 359, 
433 to 444, 459 to 466 and 467 to  476  were  involved  in  
 




Table 3. Secondary structure prediction. 
 
Helix  Sheet  Coil 
JPRED PSIPRED SABLE  JPRED PSIPRED SABLE  JPRED PSIPRED SABLE 
3-8 4-15 3-10  75-79 76-82 74-79  1-2 1-3 1-2 
28-34 28-33 28-34  83-87 85-88 84-87  9-52 34-53 35-54 
100-104 54-67 55-62  92-97 93-97 92-97  65-74 68-75 63-73 
110-122 100-104 110-122  156-160 159-163 156-160  105-109 105-110 104-109 
136-149 110-126 136-150  209-214 211-216 209-213  123-135 127-137 123-135 
166-181 138-152 165-180  287-293 289-295 287-293  150-155 153-158 151-155 
222-226 166-184 219-227  319-323 324-328 332-336  182-191 185-192 181-208 
306-315 220-230 264-280  349-359 354-357 352-355  197-265 231-263 228-263 
326-330 264-283 306-328  433-440 431-440 439-444  283-286 284-288 281-286 
363-366 308-320 336-342  459-461 465-467 463-466  294-305 296-307 294-305 
383-397 340-345 364-370  467-471 473-476 471-475  331-348 329-339 327-336 
401-422 369-372 386-401      354-362 346-353 356-363 
444-455 388-403 405-425      367-378 373-387 371-385 
478-494 406-427 450-459      398-400 428-430 445-448 
 449-462 482-500      423-432 434-439 460-462 
 483-500       441-458 477-482 467-470 
        462-466  476-481 




Beta strands formation, whereas residues from 1 to 3, 34 
to 54, 65 to 75, 105 to 110, 123 to 137, 150 to 110, 123 
to 137, 150 to 158, 182 to 208, 231 to 263, 283 to 286, 
294 to 307, 331 to 348, 354 to 362, 367 to 387, 423 to 
430, 441 to 458, 462 to 470 and 472 to 481 were 
involved in coils formation. 
 
 
3D structure prediction via homology modeling 
 
We employed a homology search in PDB database using 
BLAST and PSIBLAST to identify potential templates. 
The significant templates obtained were of Sus scrofa 
(pig) with 95.87% identity, B. taurus (bovine) with 94% 
identity, R. norvegicus (rat) with 91% identity and M. 
musculus (mouse) with 91% identity. However, we 
selected GABT_PIG (SWISS ID: P80147, PDB ID: 
1OHV) as a template for GABA-AT modeling because its 
crystal structure has been reported. After identification of 
the best template for modelling, an optimal alignment was 
made. This seems to be the most crucial step in 
homology modeling. Here “optimal” means that corres-
ponding sequence positions in target and template were 
identified, so that the predicted structure of the target, 
based on the template, is as similar as possible to an 
experimental structure of the same target. Pair-wise 
comparison between the target GABA-AT amino acid 
sequence with the template amino acid sequence of 
GABT_PIG indicate approximately 95% identity as shown 
in Figure 4. The three-dimensional structure of a protein 
is a key to understanding its function. Once the template 
is   selected   on   an   alignment   performed,   target   on 
template was mapped which transfers the coordinates 
from the template to the target of structurally conserved 
regions. Figure 5 shows the 3D structure of GABA-AT 
using SWISSMODEL. Homolgy Modeling performed by 
MODWEB showed the following result: the template 
structure used by MODWEB had a PDB id 1ohv. The 
sequence identity which shows the percentage of 
identical residues between the template and target 
alignment was shown to be 96% for our target sequence. 
Here the sequence identity result was 96% which is a 
positive sign towards accurate model having the best 
possible template. The model reliability score known as 
Model Score for our target sequence was 1.00. If a model 
score is higher than a pre-specified cutoff (0.7), then the 
predicted model is considered to be a good model. The 
template modeled residue range was 39 to 499. 
The MODPIPE protein quality score (MPQS) which is a 
composite score based upon the sequence identity of 
target to template, coverage and three scores (e-value, z-
Dope and GA341) for our protein was 2.14803. The 
MPQS greater than 1.1 is considered to be reliable 
(Pieper et al., 2004). The sequence model coverage 
which shows the modeled area of the target sequence 
was represented by different colors. The significance of 
best model is shown by colors. The model coverage 
sketch had 4 lines. The top line represents the sequence 
identity of template with the target and if it is greater than 
30%, it is shown by green color and if less than 30%, it is 
represented by red color .The second line which 
represents the template to target E-value is shown by 
green if E-value < = 0.0001 and is shown by red if E-
value >0.0001. The model  score  is  represented  by  the  
 












Figure 5. Ribbon representation of the modeled GABA-AT protein using Rasmol visualization 
software. 
 






















third line and is green if model score ≥0.7 and is red if < 
0.7 (Pieper et al., 2004). The modeled region is 
represented by the last line of the sketch (Pieper et al., 
2004). In our results, the model coverage sketch showed 
the 3 lines in green which made it a more reliable 
predicted structure. The sketch is shown in Figure 6. 
The putative ligand binding sites of MODBASE models 
were derived from the template. Figure 7 displays the 
same information as the general model coverage sketch. 
Additionally, it displays the position of the amino acid 
residues which are putative ligand binding residues as 
shown in   Figure   8.   The   3D   coordinate   file   of   the                   
model in PDB format was generated after comparative 
modeling of the target with the template by MODWEB 
shown in Figure 9. This PDB file was viewed using visual 
molecular dynamics (VMD) software and Rasmol. The 
overall summary of GABA-AT protein obtained from 
SWISSMODEL and MODWEB was classified as 22 
strands, 21 helices and 44 turns and number of hydrogen 
bonds was 317. The results from SWISS MODEL and the 
predicted protein almost coincided to be exactly and also 
showed a high degree of conservity to the template used. 
ANOLEA, GROMOS and VERIFY 3D were used to 
validate the model (Figure 10). 
 


















Knowledge of the three-dimensional structure of GABA-
AT would greatly advance the development of novel lead 
compounds targeting this molecule. As the structure of 
GABA-AT protein is  known  from  this  study,  novel  lead 
compounds can be designed on the basis of ligand 
protein interaction (docking) scores of available anti-
epileptic drugs defining the highest dockable compound 
and designing various analogues of the presently 
available drugs or defining a novel molecule on the basis 
of different binding sites.  This  will  be  useful  for  further  
 










protein-protein interaction prediction, protein-protein 
docking, molecular docking and pharmacological studies. 
However, before using the model for further work, it 
should be checked for its geometrical, stereo chemical 
and conformational accuracy before taking up for rational 
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